Prim-O-glucosylcimifugin

Cat. No.: HY-N0635 Purity: 99.94%: FAQs
Data Sheet SDS COA Handling Instructions

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

For research use only. We do not sell to patients.

Prim-O-glucosylcimifugin Chemical Structure

CAS No. : 80681-45-4

Size	Price	Stock	Quantity
Solution
10 mM * 1 mL in DMSO	USD 155	In-stock	Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL ready for reconstitution	USD 155	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 71	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 270	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

2 Publications Citing Use of MCE Prim-O-glucosylcimifugin

: Prim-O-glucosylcimifugin purchased from MCE. Usage Cited in: Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384. [Abstract]; RAW 264.7 cells are treated with Lipopolysaccharide (1 μg/mL) and various concentrations of prim-O-glucosylcimifugin (15, 50 and 100 μg/mL) and harvest at 4 h posttreatment. Cells treated with DMSO are set as control. p-JAK2, JAK2, p-STAT3, and STAT3 are detected by Western blotting.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

IC₅₀ & Target^[1]

iNOS

COX-2

In Vitro

Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. The cytotoxicity of Prim-O-glucosylcimifugin is measured to LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages are treated with LPS (1 μg/mL) and increasing concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h and cell viability is evaluated by CCK-8 assay. Cell viability is not significantly affected after 24 h and exposure to 15-100 μg/mL Prim-O-glucosylcimifugin as compared with DMSO-treated cells (control). To investigate the anti-inflammatory effect of Prim-O-glucosylcimifugin, whether Prim-O-glucosylcimifugin can affect NO synthesis is examined in LPS-activated RAW 264.7 cells. Macrophages are treated with LPS (1 μg/mL) and various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL) for 24 h. No concentrations are measured in the culture supernatants by Griess reaction. The concentrations of NO in the culture supernatants are markedly increased in response to LPS exposure, and Prim-O-glucosylcimifugin significantly inhibits LPS-induced NO production in a concentration-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and the cytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

468.45

Appearance

Solid

Formula

C₂₂H₂₈O₁₁

CAS No.

80681-45-4

SMILES

COC1=C(C[C@@H](C(C)(O)C)O2)C2=CC(OC(CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=C4)=C1C4=O

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 150 mg/mL (320.20 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1347 mL	10.6735 mL	21.3470 mL
5 mM	0.4269 mL	2.1347 mL	4.2694 mL
10 mM	0.2135 mL	1.0673 mL	2.1347 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.44 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (4.44 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.44 mM); Clear solution

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (248 KB) HNMR (273 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Zhou J, et al. Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384. [Content Brief]

[2]. Chen N, et al. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2013 Jun;16(2):139-47. [Content Brief]

Cell Assay ^[1]	Cell Counting Kit (CCK-8) is used to determine the cytotoxic concentrations of Prim-O-glucosylcimifugin. In brief, the Raw 264.7 cells are plated at a density of 1×10⁴ cells per well in a 96-well and incubated overnight. Cells are then stimulated with 1 μg/mL LPS and treated with various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/mL; MedChem Express, Princeton, NJ, USA) or DMSO. After incubation at 37°C for 24 h, CCK-8 solution is added to each well and incubated for another 1 h. The absorbance is measured at 450 nm using a microplate reader^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] BALB/c male mice, 8 weeks old and weighing approximately 18 to 20 g, are used. The mice are randomly divided into five groups: Control group; LPS group; LPS+Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg bodyweight). Prime-O-glucosylcimifugin is given intraperitoneally. One hour later, LPS group and LPS+Prime-O-glucosylcimifugin group mice are given 50 μL LPS intranasally (i.n) (200 mg/L) to induce acute lung injury. Control mice are given 50 μL PBS intranasally (i.n) without LPS^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Zhou J, et al. Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384. [Content Brief] [2]. Chen N, et al. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2013 Jun;16(2):139-47. [Content Brief]